Latest News
Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial
29 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ: NTRA) and Aveta Biomics Inc, a clinical-stage immuno-oncology company, on Monday announced a strategic partnership to support Aveta's global Phase 3 registrational t...
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device
29 June 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq: UTHR) announced on Monday that it has received U.S. Food and Drug Administration premarket approval for the LungFX device, the first system approved for centralised ex vivo...
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of upadacitinib for adult...
Neurogene reports durable positive long-term results from NGN-401 gene therapy in Rett syndrome trial
29 June 2026 - Genetic medicine company Neurogene Inc (NASDAQ: NGNE) on Monday reported updated positive long-term clinical data from its Phase 1/2 trial of NGN-401 gene therapy in females with Rett syndrome, showing sustained and progressive develop...
Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria
29 June 2026 - Biotechnology company Evommune Inc (NYSE: EVMN) disclosed on Monday that its Phase 2b trial evaluating EVO756 in moderate-to-severe chronic spontaneous urticaria did not meet its primary endpoint.The randomised, double-blind, placebo-c...